Public Assessment Report. Scientific discussion. Kaliumklorid "EQL Pharma" (Potassium chloride) DK/H/2662/001/DC. Date:

Similar documents
Public Assessment Report. Scientific discussion. Desloratadine Lek 5 mg film-coated tablets. (Desloratadine) DK/H/2041/001/DC.

Public Assessment Report. Scientific discussion. Aktiprol 50 mg, 100 mg, 200 mg and 400 mg tablets. (Amisulpride) DK/H/2386/ /DC

Public Assessment Report. Scientific discussion. Mogilarta. (Telmisartan and hydrochlorothiazide) DK/H/2306/ /DC.

Public Assessment Report. Scientific discussion. Bloxazoc 25 mg, 50 mg, 100 mg and 200 mg prolonged-release tablets Metoprolol succinate

Public Assessment Report. Scientific discussion. Propofol Hospira 10 mg/ml emulsion for injection/infusion. (Propofol) DK/H/2311/001/DC

Public Assessment Report. Scientific discussion. Tevaltan comp. Film-coated tablets 80 mg/12.5 mg and 160 mg/25 mg. Valsartan and hydrochlorothiazide

Public Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium

Summary Public Assessment Report. Generics. Triflu Paracetamol, Ascorbic acid, Pheniramine maleate MT/H/0172/001/DC

Public Assessment Report. Scientific discussion. Colecalciferol Fresenius I.E./ml Tropfen zum Einnehmen, Lösung COLECALCIFEROL AT/H/0578/001/DC

Public Assessment Report. Scientific discussion. Tevalukast Film-coated tablets 10 mg. Montelukast sodium DK/H/1332/001/DC

Public Assessment Report. Scientific discussion. Venlafaxin SUN 37.5 mg, 75 mg and 150 mg prolonged-release tablets. (venlafaxine hydrochloride)

Public Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:

Public Assessment Report. Scientific discussion. Citalopram Jubilant 10 mg, 20 mg, 30 mg and 40 mg, film-coated tablets.

Public Assessment Report. Scientific discussion. Diliban Retard Tramadol/Paracetamol IS/H/0168/001/DC. Date:

Public Assessment Report. Scientific discussion. Granon (Acetylcysteine) DK/H/2352/ /MR. Date:

Public Assessment Report. Scientific discussion. Thyrofix 25, 50, 75 and 100 micrograms tablets. (levothyroxine sodium) NL/H/3039/ /DC

Public Assessment Report. Scientific discussion. Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/ /MR

Public Assessment Report. Scientific discussion. Acetylcysteine YES 600 mg, effervescent tablets. (acetylcysteine) NL/H/2975/001/DC

Public Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.

Public Assessment Report. Scientific discussion. Lorazepam GenRx 1 mg and 2.5 mg tablets. (lorazepam) NL/H/3485/ /DC

Summary Public Assessment Report. Generics. Rosuvastatin Galenicum 5mg, 10mg, 20mg and 40mg film-coated tablets Rosuvastatin Calcium

Decentralised Procedure. Public Assessment Report. Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten. Lorazepam DE/H/4558/ /DC

Public Assessment Report Scientific discussion. Heracillin, 1 g, film-coated tablet (flucloxacillin) Asp no:

Summary Public Assessment Report. Generics. Amiodarona Aurobindo. 200 mg, Tablets. (Amiodarone hydrochloride) PT/H/1444/001/DC

Decentralised Procedure. Public Assessment Report. ALGOTRA 37.5 mg/325 mg überzogene Tabletten Tramadol/Paracetamol DE/H/3688/001/DC

Health Products Regulatory Authority IPAR. Public Assessment Report. Scientific discussion

Summary Public Assessment Report. Generics. Fluoxetina Aurobindo PT/H/1137/ /DC. Date:

Public Assessment Report. Scientific discussion. Sildenafil CF 20 mg, film-coated tablets. (sildenafil citrate) NL/H/3630/001/DC

Public Assessment Report. Scientific discussion. Tevalukast Chewable tablets 4 mg and 5 mg. Montelukast sodium DK/H/1331/ /DC

Public Assessment Report. Scientific discussion MINOXIDIL AT/H/0638/ /DC. Date:

Public Assessment Report. Scientific discussion. Celecoxib Apotex 100 mg and 200 mg, capsules, hard (celecoxib) NL/H/2760/ /DC

Public Assessment Report. Scientific discussion. Sertraline Apotex 50 mg and 100 mg, film-coated tablets (sertraline hydrochloride)

Decentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack

Public Assessment Report. Scientific discussion. Acetylsalicylzuur Disphar 500 mg and 1000 mg, oral powder. (acetylsalicylic acid)

Public Assessment Report. Scientific discussion. Hydroxyzinhydrochlorid EQL Pharma (Hydroxyzine hydrochloride) Film-coated tablet, 25 mg

Public Assessment Report. Scientific discussion. Risedronaatnatrium Aurobindo 75 mg, film-coated tablets. (risedronate sodium) NL/H/2263/004/DC

Decentralised Procedure. Public Assessment Report. Metamizol Midas / Metamizol STADA / Mimetanal 500 mg Tabletten. Metamizole sodium monohydrate

Summary Public Assessment Report. Generics. Etoricoxib Aurobindo. 30 mg, 60 mg, 90 mg, 120 mg Film-coated tablet (Etoricoxib) PT/H/1603/ /DC

Summary Public Assessment Report. non-generics. Folic acid Colonis Folic acid MT/H/0203/001/DC

Public Assessment Report. Scientific discussion. Enolwen (oxycodone hydrochloride and naloxone hydrochloride dehydrate) SE/H/1510/01-04/DC

Public Assessment Report. Scientific discussion. Elisox 50 microgram/actuation, nasal spray, suspension. (mometasone furoate) NL/H/2672/001/DC

Public Assessment Report. Mebeverine hydrochloride 50mg/5ml Oral Suspension. (Mebeverine hydrochloride) UK Licence No: PL 44710/0024

Decentralised Procedure. Public Assessment Report. Memantin Orion 10/20 mg Filmtabletten. Memantine hydrochloride DE/H/3653/ /DC

Public Assessment Report. Scientific discussion. Ramipril Teva 1.25 mg, 2.5 mg, 5 mg and 10 mg tablets Ramipril DK/H/2130/ /DC.

Public Assessment Report. Scientific discussion. Etoricoxib Glenmark 30 mg, 60 mg, 90 mg and 120 mg, film-coated tablets.

Public Assessment Report. Scientific discussion. Ipratropiumbromide/Salbutamol Cipla 0.5 mg/2.5 mg per 2.5 ml, nebuliser solution

Public Assessment Report. Scientific discussion. Midazolam Orpha 15 mg, film-coated tablets (midazolam maleate) NL/H/2815/001/DC.

Public Assessment Report Scientific discussion. Rosuvastatin/Amlodipine 10 mg/5 mg, 10 mg/10 mg, 20 mg/5 mg and 20 mg/10 mg film-coated tablets

Public Assessment Report. Scientific discussion. Rizatriptan Apotex disper 5 mg and 10 mg, orodispersible tablets. (rizatriptan benzoate)

Public Assessment Report. Scientific discussion. Etoricoxib Mylan 30 mg, 60 mg, 90 mg and 120 mg, film-coated tablets.

Public Assessment Report. Scientific discussion. Levofloxacin Bluefish (levofloxacin hemihydrate) SE/H/889/01-02/DC

Public Assessment Report Scientific discussion. Ciprofloxacin Accord (ciprofloxacin hydrochloride) SE/H/1026/01-03/DC

Public Assessment Report Scientific discussion. Trelema (lacosamide) SE/H/1648/01-07/DC

Public Assessment Report Scientific discussion. Flucloxacillin Orion (flucloxacillin sodium) SE/H/981/03/DC

Public Assessment Report Scientific discussion. Vixantus (tadalafil) SE/H/1532/01-04/DC

Public Assessment Report. Scientific discussion. Abacavir/Lamivudine/Zidovudine Mylan 300 mg/ 150 mg/300 mg, film-coated tablets

Public Assessment Report Scientific discussion. Metoclopramide Orion (metoclopramide hydrochloride) SE/H/1445/01/DC

Public Assessment Report Scientific discussion. Ivabradine Grindeks 5 mg and 7.5 mg and filmcoated. Ivabradine hydrochloride ES/H/0375/ /DC

Public Assessment Report. Scientific discussion

Public Assessment Report Scientific discussion. Oxikodon Actavis (oxycodone hydrochloride) SE/H/1226/01-03/DC

Decentralised Procedure. Public Assessment Report. Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten

Public Assessment Report Scientific discussion. Deferiprone DOC (deferiprone) SE/H/1687/01-02/DC

Public Assessment Report. Scientific discussion. Valganciclovir Mylan 450 mg, film-coated tablets. (valganciclovir hydrochloride) NL/H/3035/001/DC

Public Assessment Report Scientific discussion. Acetylsalicylsyra Actavis (acetylsalicylic acid) SE/H/1020/ /DC

Public Assessment Report Scientific discussion. Quetiapin Orion (quetiapine fumarate) SE/H/1115/01-04/DC

Public Assessment Report. Scientific discussion. Amlodipine/Valsartan Apotex 5 mg/80 mg, 5 mg/160 mg and 10 mg/160 mg, film-coated tablets

Public Assessment Report Scientific discussion. Rizatriptan Orifarm (rizatriptan) SE/H/1104/01-02/DC

Public Assessment Report Scientific discussion. Ciprofloxacin Pfizer (Ciprofloxacin hydrochloride) SE/H/803/01-03/DC

Ciprofloxacin Bluefish (Ciprofloxacin hydrochloride)

Public Assessment Report Scientific discussion. Oxikodon Depot Actavis (oxycodone hydrochloride) SE/H/1313/01-08/DC

Public Assessment Report. Scientific discussion. Pregabalin Orion (pregabalin) SE/H/1440/01-07/DC

Public Assessment Report. Scientific discussion. Colecalciferol Benferol 800 IE soft capsules. (cholecalciferol) NL/H/3391/001/DC

Public Assessment Report Scientific discussion. Pramipexole Orion (pramipexole) SE/H/1672/01-07/DC

Public Assessment Report Scientific discussion

Public Assessment Report Scientific discussion. Divisun (colecalciferol) SE/H/1122/02-04/DC

Public Assessment Report Scientific discussion SE/H/1689/01/DC

Public Assessment Report Scientific discussion. Dexametason Abcur Dexamethasone SE/H/1260/01-02/DC

DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Decentralised Procedure. Public Assessment Report

Public Assessment Report. Scientific discussion. Pemetrexed SUN 100 mg, 500 mg and 1000 mg powder for concentrate for solution for infusion

Decentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC

Public Assessment Report. Scientific discussion. Alfuzosine HCl Aurobindo 10 mg, prolonged-release tablets. (alfuzosin hydrochloride) NL/H/3015/001/MR

Public Assessment Report. Scientific discussion. Metoprololsuccinat Actavis. Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg

Decentralised Procedure. Public Assessment Report

Public Assessment Report Scientific discussion. Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC

Decentralised Procedure. Public Assessment Report. Memantin Pharmascope 10 / 20 mg Filmtabletten Memantine hydrochloride DE/H/3673/ /DC

Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets. (Eprosartan mesilate) PL 37222/

Decentralised Procedure. Public Assessment Report. Budesonid Sandoz 32 / 64 Mikrogramm/Sprühstoß Nasenspray, Suspension.

Public Assessment Report. Scientific discussion. Supliven, concentrate for solution for infusion

Public Assessment Report Scientific discussion. Nicorette Pepparmint (nicotine) SE/H/904/01/DC

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion. Leflunomide Apotex 10 mg and 20 mg, tablets. (leflunomide) NL/H/2548/ /DC

Public Assessment Report Scientific discussion. Losartan/Hydrochlorothiazide Bluefish (losartan/hydrochlorothiazide) SE/H/780/01-02/DC

Public Assessment Report. Scientific discussion. Eviana SE/H/150/02/MR

Public Assessment Report Scientific discussion. Modafinil Bluefish (modafinil) SE/H/1325/01/DC

Public Assessment Report Scientific discussion. Aspirin (acetylsalicylic acid) Asp no:

Public Assessment Report Scientific discussion. Ibuprofen 400 mg/100 ml solution for infusion & Ibuprofen 600 mg/100 ml solution for infusion

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

Public Assessment Report Scientific discussion. Levodopa/Carbidopa/Entacapone Mylan (levodopa, carbidopa, entacapone) SE/H/1548/01-06/DC

Public Assessment Report. Scientific discussion. Valsartan/HCT Jubilant 80/12.5 mg and 160/25 mg film-coated tablets. (valsartan, hydrochlorothiazide)

Transcription:

CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Kaliumklorid "EQL Pharma" (Potassium chloride) DK/H/2662/001/DC Date: 16-06-2017 This module reflects the scientific discussion for the approval of Kaliumklorid "EQL Pharma". The procedure was finalised on 09-05-2017. For information on changes after this date please refer to the module Update.

I. INTRODUCTION Based on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Kaliumklorid EQL Pharma, from EQL Pharma. The product is indicated for: Hypokalaemia. Prevention of hypokalaemia in treatment with diuretics. A comprehensive description of the indications and posology is given in the SmPC. This decentralised procedure concerns a generic application claiming essential similarity with the reference product Kaleorid (MA number in the RMS Denmark: 04936) which has been registered in RMS by LEO Pharma A/S since 1966. The applicant has submitted a bioequivalence study in which the pharmacokinetic profile of the product is compared with the pharmacokinetic profile of the reference product Kaleorid, registered in Sweden. This generic product can be used instead of its reference product. The marketing authorisation is granted based on article 10.1 of Directive 2001/83/EC. II. II.1 QUALITY ASPECTS Introduction Kaliumklorid "EQL Pharma" prolonged-release tablet contains 750 mg potassium chloride. The film-coated prolonged-release tablets are opaque white to pearl white, oval 16x8 mm, plain tablet. Kaliumklorid "EQL Pharma" is packed in a HDPE bottle with a polypropylene screw cap in pack-sizes of 100 or 250 tablets. However, not all pack-sizes may be marketed. The excipients are Silica Colloidal Anhydrous, Ethylcellulose, Stearyl Alcohol, Hypromellose and Talc. Film-coating: Ethyl cellulose, Medium chain triglycerides, Oleic acid Compliance wih Good Manufacturing Practice The RMS has been assured that acceptable standards of GMP (see Directive 2003/94/EC) are in place for this product type at all sites responsible for the manufacture and assembly of this product prior to granting its national authorisation. II.2 Drug Substance There is a monograph for the active substance potassium chloride in Ph.Eur. A CEP (Certificate of suitability) has been granted for the active ingredient by EDQM (European Directorate for the Quality of Medicines & Health Care). The control tests and specifications for drug substance have been adequately drawn up. PAR Scientific discussion 2/6

II.3 Medicinal Product The development of the product has been described, the choice of excipients has been justified and their functions explained. A satisfactory batch formula has been provided for the manufacture of the product along with an appropriate account of the manufacturing process. Process validations have been carried out and the results are satisfactory. The product specifications cover appropriate parameters for this dosage form. Validations of the analytical methods have been presented. Batch analysis results have been presented from several batches of both strengths. The batch analysis results show that the finished products meet the specifications proposed. The conditions used in the stability studies are according to the ICH stability guideline. The control tests and specifications for drug product are adequately drawn up. The shelf-life of three years without any special storage conditions when stored in HDPE container with a polypropylene screw cap is considered acceptable for the drug product. II.4 Discussion on chemical, pharmaceutical and biological aspects The chemical-pharmaceutical documentation in relation to the active substance and final product are of sufficient quality in view of the present European regulatory requirements. III. III.1 NON-CLINICAL ASPECTS Introduction Pharmacodynamic, pharmacokinetic and toxicological properties of potassium chloride are well known. As potassium chloride is a widely used well-known active substance, the applicant has not provided additional studies and further studies are not required. Overview based on literature review is, thus, appropriate. The non-clinical overview report refers numerous publications up to year 2012. The nonclinical overview on the pre-clinical pharmacology, pharmacokinetics and toxicology is adequate. III.2 Ecotoxicity/environmental risk assessment (ERA) Since Kaliumklorid EQL Pharma is intended for generic substitution, this will not lead to an increased exposure to the environment. An environmental risk assessment is therefore not deemed necessary. IV. IV.1 CLINICAL ASPECTS Introduction Potassium chloride is a well-known active substance with established efficacy and tolerability. As potassium chloride is a widely used, well-known active substance, the applicant has not PAR Scientific discussion 3/6

provided additional studies (apart from a supportive bioequivalence study referenced below) and further studies are not required. Overview based on literature review is, thus, appropriate. The clinical report refers 11 publications up to 2014. The clinical overview on the clinical pharmacology, efficacy and safety is adequate. IV.2 Pharmacokinetics For this generic application, the MAH has submitted one bioequivalence study in which the pharmacokinetic profile of the test product Kaliumchlorid EQL Pharma is compared with the pharmacokinetic profile of the reference product <insert name, company and country of origin. Bioequivalence study To support the application the applicant has submitted 1 bioequivalence study (single-dose, 2- way crossover under fasting conditions, based on urinary excretion of potassium) with Kaliumklorid EQL 750mg (x8) prolonged release tablets by EQL Pharma which has been compared to Kaleorid 750mg (x8) prolonged release tablets, LEO from the Swedish market. 42 subjects participated in the study and 42 subjects completed the study and were analysed. Bioequivalence between the test and the reference product has been demonstrated. Results on Primary parameters analysed (Ae0-24 and Rmax) fall within the acceptance range of 80.00-125.00% for both methods of subtraction of baseline data of potassium excretion, and are within the acceptance range 80.00-125.00% for results calculated with initial values only (for re-assayed samples) and are within the acceptance range. Conclusion on bioequivalence studies: Based on the submitted bioequivalence study Kaliumklorid EQL Pharma is considered bioequivalent with Kaleorid. IV.3 Risk Management Plan The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Kaliumklorid EQL Pharma. Table 1: Summary of safety concerns Summary of safety concerns Important identified Hyperkalaemia risks a) in patients with renal insufficiency, untreated Addison s disease or severe electrolyte imbalance. b) in patients co-administered with ACE inhibitors, angiotensin-ii-receptor antagonists, ciclosporin, NSAIDs, β-blockers, heparin, digoxin, potassium sparing diuretics. Hypersensitivity Gastrointestinal ulcers Important potential risks Intentional or unintentional overdose of potassium chloride. Increased gastrointestinal adverse effects under coadministration with anticholinergics/antimuscarinics PAR Scientific discussion 4/6

Summary of safety concerns Missing information Use of potassium chloride in children The safety concerns are considered satisfactory. Table 2: Summary table of Risk Minimisation Measures Safety concern Hyperkalaemia a) in patients with renal insufficiency, untreated Addison s disease or severe electrolyte imbalance. b) in patients co-administered with ACE inhibitors, angiotensin-iireceptor antagonists, ciclosporin, NSAIDs, β-blockers, heparin, digoxin, potassium sparing diuretics. Routine risk minimisation measures SmPC sections 4.2, 4.3, 4.4, 4.5 & 4.8 Hypersensitivity SmPC sections 4.3 & 4.8 None Gastrointestinal ulcers SmPC sections 4.3, 4.4, 4.6 & None 4.8 Intentional or unintentional SmPC section 4.9 None overdose of potassium chloride. Increased gastrointestinal adverse effects under co-administration with anticholinergics/antimuscarinics SmPC sections 4.4 & 4.8 None Use of potassium chloride in children SmPC sections 4.2, 4.6 & 4.9 Additional risk minimisation measures None None The proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indications. V. USER CONSULTATION The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing the PIL was English. The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. The test consisted of: a pilot test with five participants, followed by two rounds with 10 participants each. The questions covered the following areas sufficiently: traceability, comprehensibility and applicability. PAR Scientific discussion 5/6

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION Kaliumklorid "EQL Pharma" prolonged-release tablets contains 750 mg potassium chloride. Kaliumklorid EQL Pharma has a proven chemical-pharmaceutical quality and is a generic form of Kaleorid. Kaleorid is a well-known medicinal product with an established favourable efficacy and safety profile. Bioequivalence has been shown to be in compliance with the requirements of European guidance documents. The MAH presented a risk management plan summarising the safety concerns. There are no additional pharmacovigilance or risk minimisation measures. Agreement between Member States was reached during a written procedure. There was no discussion in the CMDh. The Member States Concerned, on the basis of the data submitted, considered that essential similarity has been demonstrated for Kaliumklorid EQL Pharma with the reference product, and have therefore granted a marketing authorisation. The decentralised procedure was finalised on 09-05-2017. Kaliumklorid EQL Pharma was authorised in Denmark on 16-06-2017. According to the List of Union reference dates and frequency of submission of periodic safety update reports (PSURs), no routine PSURs are required for this product. The date for the first renewal will be 09-05-2022. There were no post-approval commitments made during the procedure. PAR Scientific discussion 6/6